Astrazeneca Phar

37
Sell
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE203A01020
  • NSEID: ASTRAZEN
  • BSEID: 506820
INR
7,030.00
-76.25 (-1.07%)
BSENSE

Aug 31, 02:30 PM

BSE+NSE Vol: 2.31 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025

Compare Profit and Loss Results of Astrazeneca Phar
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
2,275.00
1,697.00
578.00
34.06%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
2,275.00
1,697.00
578.00
34.06%
Expenditure (Ex Depriciation)
Stock Adjustments
-488.00
-43.00
-445.00
-1,034.88%
Raw Materials Consumed
1,868.00
542.00
1,326.00
244.65%
Power & Fuel Cost
2.00
4.00
-2.00
-50.00%
Employee Cost
264.00
361.00
-97.00
-26.87%
Operating Expenses
20.00
22.00
-2.00
-9.09%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
124.00
124.00
0.00
0.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
31.00
106.00
-75.00
-70.75%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,013.00
1,211.00
802.00
66.23%
Operating Profit (PBDIT) excl Other Income
262.00
486.00
-224.00
-46.09%
Other Income
28.00
35.00
-7.00
-20.00%
Operating Profit (PBDIT)
290.00
522.00
-232.00
-44.44%
Interest
4.00
220.00
-216.00
-98.18%
Profit before Depriciation and Tax
286.00
301.00
-15.00
-4.98%
Depreciation
28.00
181.00
-153.00
-84.53%
Profit Before Taxation & Exceptional Items
257.00
120.00
137.00
114.17%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
252.00
120.00
132.00
110.00%
Provision for Tax
64.00
42.00
22.00
52.38%
Profit After Tax
187.00
77.00
110.00
142.86%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
632.00
2,487.00
-1,855.00
-74.59%
Profit Available for appropriations
820.00
2,564.00
-1,744.00
-68.02%
Appropriations
820.00
2,564.00
-1,744.00
-68.02%
Equity Dividend (%)
1800%
735%
1,065.00
Earnings Per Share
75.01
5.69
69.32
1,218.28%
Profit And Loss - Net Sales
Net Sales 2,275.58 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 262.03 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025

Profit And Loss - Interest
Interest 4.49 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025

Profit And Loss - Profit After Tax
Profit After Tax 187.52 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025